Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Tamás G. Gergely"'
Autor:
Csenger Kovácsházi, Szabolcs Hambalkó, Nabil V. Sayour, Tamás G. Gergely, Gábor B. Brenner, Csilla Pelyhe, Dóra Kapui, Bennet Y. Weber, Alexander L. Hültenschmidt, Éva Pállinger, Edit I. Buzás, Ádám Zolcsák, Bálint Kiss, Tamás Bozó, Csilla Csányi, Nikolett Kósa, Miklós Kellermayer, Róbert Farkas, Gellért B. Karvaly, Kieran Wynne, David Matallanas, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Hypercholesterolemia (HC) induces, propagates and exacerbates cardiovascular diseases via various mechanisms that are yet not properly understood. Extracellular vesicles (EVs) are involved in the pathomechanism of these diseases. To understa
Externí odkaz:
https://doaj.org/article/af891ef4f6eb4aa6a97926bd769c49dc
Autor:
Dániel Kucsera, Viktória E. Tóth, Nabil V. Sayour, Tamás Kovács, Tamás G. Gergely, Mihály Ruppert, Tamás Radovits, Alexandra Fábián, Attila Kovács, Béla Merkely, Péter Ferdinandy, Zoltán V. Varga
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Interleukin-1β (IL-1β) is a key mediator of non-alcoholic steatohepatitis (NASH), a chronic liver disease, and of systemic inflammation-driven aging. IL-1β contributes to cardio-metabolic decline, and may promote hepatic oncogenic transfo
Externí odkaz:
https://doaj.org/article/4c0e61863a41496687dce854be03e766
Autor:
Nabil V. Sayour, Viktória É. Tóth, Regina N. Nagy, Imre Vörös, Tamás G. Gergely, Zsófia Onódi, Noémi Nagy, Csaba Bödör, Barnabás Váradi, Mihály Ruppert, Tamás Radovits, Federico Bleckwedel, Laura C. Zelarayán, Pal Pacher, Bence Ágg, Anikó Görbe, Péter Ferdinandy, Zoltán V. Varga
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 18, p 13826 (2023)
The identification of novel drug targets is needed to improve the outcomes of heart failure (HF). G-protein-coupled receptors (GPCRs) represent the largest family of targets for already approved drugs, thus providing an opportunity for drug repurposi
Externí odkaz:
https://doaj.org/article/cf0ec70700ff485780b6aa30bc1f3382
Autor:
Tamás G. Gergely, Gábor B. Brenner, Regina N. Nagy, Nabil V. Sayour, András Makkos, Csenger Kovácsházi, Huimin Tian, Rainer Schulz, Zoltán Giricz, Anikó Görbe, Péter Ferdinandy
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 2, p 1585 (2023)
Lipid-lowering drugs have been shown to have cardioprotective effects but may have hidden cardiotoxic properties. Therefore, here we aimed to investigate if chronic treatment with the novel lipid-lowering drug bempedoic acid (BA) exerts hidden cardio
Externí odkaz:
https://doaj.org/article/17e87be51e874adc966ccfd71a3a1ed0
Autor:
Bennet Y. Weber, Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1055 (2022)
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during p
Externí odkaz:
https://doaj.org/article/be592a902bfc4549be3705bd481e22c9
Autor:
Imre Vörös, Zsófia Onódi, Viktória Éva Tóth, Tamás G. Gergely, Éva Sághy, Anikó Görbe, Ágnes Kemény, Przemyslaw Leszek, Zsuzsanna Helyes, Péter Ferdinandy, Zoltán V. Varga
Publikováno v:
Biomedicines, Vol 10, Iss 7, p 1573 (2022)
Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinical trial revealed increased heart-failure-associated hospitalization in saxagliptin-treated patients. Although this side effect could limit therapeutic
Externí odkaz:
https://doaj.org/article/b9b1068e730841bcbfb1bdb37cef836e
Autor:
Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi, Nabil V. Sayour, Tamás G. Gergely, Bernadett Kiss, Anikó Görbe, Éva Sághy, Zoltán S. Zádori, Bernadette Lázár, Tamás Baranyai, Richárd S. Varga, Zoltán Husti, András Varró, László Tóthfalusi, Rainer Schulz, István Baczkó, Zoltán Giricz, Péter Ferdinandy
Publikováno v:
Cells, Vol 9, Iss 3, p 551 (2020)
Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the
Externí odkaz:
https://doaj.org/article/e64b79f188254c80abf4399ea382fcad
Autor:
Zsófia Onódi, Tamás Visnovitz, Bernadett Kiss, Szabolcs Hambalkó, Anna Koncz, Bence Ágg, Barnabás Váradi, Viktória É. Tóth, Regina N. Nagy, Tamás G. Gergely, Dorottya Gergő, András Makkos, Csilla Pelyhe, Nóra Varga, Dóra Reé, Ágota Apáti, Przemyslaw Leszek, Tamás Kovács, Nándor Nagy, Péter Ferdinandy, Edit I. Buzás, Anikó Görbe, Zoltán Giricz, Zoltán V. Varga
Publikováno v:
Journal of Molecular and Cellular Cardiology
Cardiac cell lines and primary cells are widely used in cardiovascular research. Despite increasing number of publications using these models, comparative characterization of these cell lines has not been performed, therefore, their limitations are u
Autor:
Nabil V Sayour, Gábor B Brenner, András Makkos, Bernadett Kiss, Csenger Kovácsházi, Tamás G Gergely, Sverre Groever Aukrust, Huimin Tian, Viktória Zenkl, Kamilla Gömöri, Tamara Szabados, Péter Bencsik, Andre Heinen, Rainer Schulz, Gary F Baxter, Coert J Zuurbier, Zoltán Vokó, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Caridovascular Research
Aims Remote ischaemic preconditioning (RIPC) is a robust cardioprotective intervention in preclinical studies. To establish a working and efficacious RIPC protocol in our laboratories, we performed randomized, blinded in vivo studies in three study c
Autor:
Tamás G, Gergely, Dániel, Kucsera, Viktória E, Tóth, Tamás, Kovács, Nabil V, Sayour, Zsófia D, Drobni, Mihály, Ruppert, Balázs, Petrovich, Bence, Ágg, Zsófia, Onódi, Nóra, Fekete, Éva, Pállinger, Edit I, Buzás, Laura I, Yousif, Wouter C, Meijers, Tamás, Radovits, Béla, Merkely, Péter, Ferdinandy, Zoltán V, Varga
Publikováno v:
British journal of pharmacology.
Immune checkpoint inhibitors (ICI), such as anti-PD-1 monoclonal antibodies, have revolutionized cancer therapy by enhancing cytotoxic effects of T cells against tumours. However, enhanced T cell activity may cause myocarditis and cardiotoxicity. Nev